News

UC San Francisco will be the first hospital in California, and one of only a few nationwide, to offer pharmacogenetic testing.

Psilocybin is a hallucinogenic compound found in about 200 mushroom species, including the liberty cap. For millennia, our ancestors have known and used this substance, and in recent years, it has received renewed interest from scientific researchers and therapists.

The first participant has received a dose of a new Zika virus vaccine being trialled by the University of Liverpool at the Clinical Research Facility within the Royal Liverpool University Hospital.

Scientists have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease.

A first-in-human clinical trial has successfully delivered chemotherapy drugs through the blood–brain barrier using ultrasound, with the potential to aid treatment for the deadly brain cancer glioblastoma.

Modeling the pharmacological properties of the African psychedelic plant medicine ibogaine, researchers have developed two novel drug candidates for treating addiction and depression. The research is published in Cell.

Ketamine can lessen the effects of depression but can also trigger dissociative symptoms—such as detachment and out-of-body experiences.

Researchers have developed a new platform to test cardiac side effects of chemotherapy using donated heart tissue from dogs.

Gene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells – can effectively eliminate HIV infection.

The International Vaccine Institute (IVI) began clinical development of DuoChol, a new low-cost oral cholera vaccine (OCV) in capsule form.